Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cancer antibody reboot blood production in aplastic anemia?

NCT ID NCT07714512

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial tests isatuximab, an antibody that targets CD38, in adults with refractory severe aplastic anemia—a condition where the bone marrow fails to produce enough blood cells. Participants receive weekly infusions for six weeks. The study aims to see if the drug is safe and can improve blood cell counts in patients who have not responded to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a CD38 monoclonal antibody called isatuximab
What this could lead to
If successful, this could offer a new treatment option for patients with severe aplastic anemia who do not respond to current therapies.
What could go wrong
This is an early-phase trial with only 32 participants, so results may not generalize. The drug may cause side effects or fail to improve blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Red Blood Cell Diseases Center and Regenerative Medicine Center

    RECRUITING

    Tianjin, Tianjin Municipality, 301617, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.